Citations

Clear

28 citation(s) found for "Sugimoto, D".

Comparison of pre-high school and high school football quarterback injuries
Kobelski, Greggory, Radel, Luke C. , Meehan, William P. , Sugimoto, Dai , Jones, Jacob C. , O’Brien, Michael John

Mayo Clinic

The Physician and Sportsmedicine | May 25, 2022 | Volume: 51 | Issue: 4 | Pages: 331-335

10.1080/00913847.2022.2082854 | PMID 35612541 Get It

Pediatric Hurdle Injuries in Track and Field: A Descriptive Epidemiologic Study
Radel, LC, Jones, JC, Garcia, KS, Soma, DB, Sugimoto, D, Sugimoto, D

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 18, 2022 | Volume: 10 | Issue: 5_suppl2 | Pages: No page available

10.1177/2325967121s00498 Get It

Background: Track & field has more combined participants compared to any other high school sport in the United States. Hurdling is a track event that is unique due to a combination of running and jumping over an apparatus. As a result, this puts athletes at risk for various musculoskeletal injuries. However, there has been a paucity of studies describing the epidemiology of pediatric hurdle injuries Purpose: To examine hurdle-related injury types, body locations, injury mechanisms, and injury settings in children and adolescents. Methods: This was a retrospective review of data that was extracted from the National Electronic Injury Surveillance System (NEISS), which represents emergency room visits. Injury data involving hurdle injuries was searched during a 10-year period (2008-2017) involving patients 18 and under. Injuries were then classified based upon injury type, body locations involved, injury mechanisms, and injury settings. Descriptive statistics were used including mean ± standard deviation and frequency (N) was expressed as percentages (%). Results: A total of 749 hurdle related injuries were found from 333 males (44.5%) and 416 females (55.5%). Their mean ages were 14.0±2.2 years. The top 3 commonly recorded injury types were traumatic fracture (N=218, 29.1%), joint sprain (N=191, 25.5%), and contusion/hematoma/bruise (N=78, 10.4%). The overall top 3 injured body locations were ankle (N=140, 18.7%), knee (N=120, 16.0%), and wrist (N=69, 9.2%). Most injury mechanisms were trips, falls, and landings involving the hurdle (N=594, 79.0%). The rest of the mechanisms included ground involvement only (N=47, 6.3%) and other equipment (N=7, 0.9%). Finally, injury settings consisted of track & field practices (N=469, 62.6%), track & field meets (N=96, 12.8%), and other settings including gym, physical education class, recess, school activities, and camps (N=49, 6.5%). Conclusion: In pediatric hurdle athletes, most injuries seen in the emergency room are due to involvement of the hurdle and most occur during track practices. Although most injuries occur in the lower extremity, upper extremity injuries are also common. This information could be helpful in playing a role in targeted event-specific injury prevention initiatives.
Sex and Age Comparisons of Pediatric Track & Field Hurdle Injuries
Radel, Luke C. , Garcia, Kyle, Soma, David , Sugimoto, Dai , Jones, Jacob C.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 18, 2022 | Volume: 10 | Issue: 5_suppl2 | Pages: No page available

10.1177/2325967121s00441 Get It

Background: Track & field has more participants compared to any other high school sport and continues to gain popularity among middle school aged kids. Among many events, hurdles is unique because there is continued running with repeated jumping over an apparatus. Although serious injury has been anecdotally reported, there are few studies describing pediatric hurdle injuries including sex and age differences. Purpose: To investigate hurdle-related injury types and body locations based on age and sex among children and adolescents. Methods: Hurdle related injury data was extracted from the National Electronic Injury Surveillance System (NEISS), which represents emergency room visits. The search period was a 10-years (2008-2017). The eligibility criteria was < 18 years of age. Injuries were then classified based upon injury type and body location(s) involved. A chi-square (x2) analysis was employed to assess proportional differences of top three hurdle related injury types and body locations by age (<14 years vs. >15 years) and sex (male vs. female). Statistical significance was set as p<0.05. Results: A total of 749 cases related to hurdle injuries were extracted. Among recorded 749 injuries, traumatic fractures (N=218, 29.1%), joint sprain (N=191, 25.5%), and contusion/hematoma/bruise (N=78, 10.4%) were found as the top three most commonly sustained injuries. Chi-square (x2)analysis found more traumatic fractures in <14 years (34.1%) compared to >15 years (21.5%, p=0.001) while more joint sprain was identified in >15 years (29.6%) than <14 years (22.8%, p=0.036). Regarding sex comparisons, males had more traumatic fractures (35.1%) than females (24.3%, p=0.001). Conversely, females sustained more joint sprains (29.1%) and contusion/hematoma/bruise (12.7%) than males (joint sprain, 21.0%, p=0.012; contusion/hematoma/bruise, 7.5%, p=0.020). The top 3 injured body locations were ankle (N=140, 18.7%), knee (N=120, 16.0%), and wrist (N=69, 9.2%). No differences were found between body locations and age; however, statistical differences were detected by sex comparisons. Ankle injury was more common in females (24.0%) than males (12.0%, p=0.001). Yet, injury at wrist was more prevalent in males (11.7%) compared to females (7.2%, p=0.034). Conclusion: Findings of this study suggest that hurdle injury types seen in the emergency room differ by sex and age: more fractures are seen in males and younger pediatric populations while more sprains are seen in females and older adolescents. These findings may be helpful in event planning and may also play a role in injury prevention.
Revisiting and Implementing the Weber and Ventilatory Functional Classifications in Heart Failure by Cardiopulmonary Imaging Phenotyping
Metra, Marco , Losito, Maurizio, Alfonzetti, Eleonora, Boveri, Sara , Sugimoto, Tadafumi , Borlaug, Barry, Metra, Marco , Guazzi, Marco , Borlaug, Barry A. , Bandera, Francesco

Mayo Clinic

Journal of the American Heart Association | February 20, 2021 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/jaha.120.018822 | PMID 33615821 Get It

Background In heart failure, the exercise gas exchange Weber (A to D) and ventilatory classifications (VC‐1 to VC‐4) historically define disease severity and prognosis. However, their applications in the modern heart failure population of any left ventricular ejection fraction combined with hemodynamics are undefined. We aimed at revisiting and implementing these classifications by cardiopulmonary exercise testing imaging. Methods and Results 269 patients with heart failure with reduced (n=105), mid‐range (n=88) and preserved (n=76) ejection fraction underwent cardiopulmonary exercise testing imaging, primarily assessing the cardiac output (CO), mitral regurgitation, and mean pulmonary arterial pressure (mPAP)/CO slope. Within both classes, a progressively lower exercise CO, higher mPAP/CO slopes, and mitral regurgitation ( P <0.01 all) were observed. After adjustment for age and sex, Cox proportional hazard regression analyses showed that Weber (hazard ratio [HR], 2.9; 95% CI, 1.8–4.7; P <0.001) and ventilatory classes (HR, 1.4; 95% CI, 1.1–2.0; P =0.017) were independently associated with outcome. The best stratification was observed when combining Weber (A/B or C/D) with severe ventilation inefficiency (VC‐4) (HR, 2.7; 95% CI, 1.6–4.8; P <0.001). At multivariable analysis the best hemodynamic determinants of peak oxygen consumption and ventilation to carbon dioxide production slope were CO (β‐coefficient, 0.72±0.16; P <0.001) and mPAP/CO slope (β‐coefficient, 0.72±0.16; P <0.001), respectively. Conclusions In the contemporary heart failure population, the Weber and ventilatory classifications maintain their prognostic ability, especially when combined. Exercise CO and mPAP/CO slope are the best predictors of peak oxygen consumption and ventilation to carbon dioxide production slope classifications representing the main targets of interventions to impact functional class and, likely, event rate.
Redistribution of cardiac output during exercise by functional mitral regurgitation in heart failure: compensatory O2 peripheral uptake to delivery failure
Generati, Greta, Alfonzetti, Eleonora, Sugimoto, Tadafumi , Borlaug, Barry, Guazzi, Marco , Borlaug, Barry A. , Castelvecchio, Serenella , Menicanti, Lorenzo , Bandera, Francesco

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | May 22, 2020 | Volume: 319 | Issue: 1 | Pages: H100-H108

10.1152/ajpheart.00125.2020 | PMID 32442022 Get It

This is an analysis involving 134 heart failure patients with reduced ejection fraction versus 80 controls investigated during functional evaluation with gas exchange and hemodynamic, addressing the severe mitral regurgitation phenotype and testing the hypothesis that the backward cardiac output redistribution to the lung during exercise impairs delivery and overexpresses peripheral extraction. This information is new and has important implications in the management of heart failure.
Youth American football quarterback injuries: a descriptive study of 15 years of retrospective data
Radel, Luke C. , Kobelski, Greggory, Meehan, William P. , Sugimoto, Dai , O’Brien, Michael J.

Mayo Clinic

The Physician and Sportsmedicine | March 31, 2020 | Volume: 48 | Issue: 4 | Pages: 463-468

10.1080/00913847.2020.1749907 | PMID 32228392 Get It

Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer
Babić, Ana , Rosenthal, Michael H. , Bamlet, William R. , Takahashi, Naoki , Sugimoto, Motokazu , Danai, Laura V. , Morales‐Oyarvide, Vicente, Khalaf, Natalia , Dunne, Richard F. , Welch, Marisa W., Zellers, Caitlin L., Dennis, Courtney , Rifai, Nader , Prado, Carla M. , Caan, Bette J. , Sundaresan, Tilak , Meyerhardt, Jeffrey A. , Kulke, Matthew H. , Clish, Clary B. , Ng, Kimmie , Petersen, Gloria M. , Wolpin, Brian M. , Vander Heiden, Matthew G , Bamlet, William R , Meyerhardt, Jeffrey A , Clish, Clary , Takahashi, Naoki , Caan, Bette J , Brais, Lauren K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 18, 2019 | Volume: 28 | Issue: 12 | Pages: 2062-2069

10.1158/1055-9965.epi-19-0370 | PMID 31533940 Get It

Abstract Background: Pancreatic cancer is associated with development of cachexia, a wasting syndrome thought to limit survival. Few studies have longitudinally quantified peripheral tissues or identified biomarkers predictive of future tissue wasting. Methods: Adipose and muscle tissue were measured by computed tomography (CT) at diagnosis and 50 to 120 days later in 164 patients with advanced pancreatic cancer. Tissue changes and survival were evaluated by Cox proportional hazards regression. Baseline levels of circulating markers were examined in relation to future tissue wasting. Results: Compared with patients in the bottom quartile of muscle change per 30 days (average gain of 0.8 ± 2.0 cm2), those in the top quartile (average loss of 12.9 ± 4.9 cm2) had a hazard ratio (HR) for death of 2.01 [95% confidence interval (CI), 1.12–3.62]. Patients in the top quartile of muscle attenuation change (average decrease of 4.9 ± 2.4 Hounsfield units) had an HR of 2.19 (95% CI, 1.18–4.04) compared with those in the bottom quartile (average increase of 2.4 ± 1.6 Hounsfield units). Changes in adipose tissue were not associated with survival. Higher plasma branched chain amino acids (BCAA; P = 0.004) and lower monocyte chemoattractant protein-1 (MCP-1; P = 0.005) at diagnosis were associated with greater future muscle loss. Conclusions: In patients with advanced pancreatic cancer, muscle loss and decrease in muscle density in 2 to 4 months after diagnosis were associated with reduced survival. BCAAs and MCP-1 levels at diagnosis were associated with subsequent muscle loss. Impact: BCAAs and MCP-1 levels at diagnosis could identify a high-risk group for future tissue wasting.
Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis
Sugimoto, Motokazu , Takahashi, Naoki , Farnell, Michael B., Smyrk, Thomas C. , Truty, Mark J. , Nagorney, David M. , Smoot, Rory L. , Chari, Suresh T. , Carter, Rickey E. , Kendrick, Michael L. , Smoot, Rory L , Carter, Rickey E , Takahashi, Naoki , Chari, Suresh T

Mayo Clinic

Journal of Surgical Oncology | August 27, 2019 | Volume: 120 | Issue: 6 | Pages: 976-984

10.1002/jso.25681 | PMID 31452208 Get It

AbstractBackground and ObjectivesConclusive evidence in favor of neoadjuvant therapy for those with non‐metastatic pancreatic ductal adenocarcinoma (PDAC) is still lacking. The objective of this study was to evaluate the survival benefit of neoadjuvant therapy vs upfront surgery for patients with non‐metastatic PDAC.MethodsThe study involved 565 patients undergoing neoadjuvant therapy or upfront surgery as the primary treatment for PDAC. Propensity score matching was performed between the neoadjuvant therapy group (NAT group) and the upfront surgery group (UFS group) using 20 clinical variables at diagnosis. Overall survival and surgical pathology were compared between the two treatment groups on an intent‐to‐treat basis.ResultsIn the matched cohort, the NAT group (n = 91) had a longer median overall survival than the UFS group (n = 91) (23.1 months vs 18.5 months, P = .043). The rate of patients undergoing surgical resection was lower in the NAT group (58% vs 80%, P = .001). Regarding surgical pathology, the NAT group had smaller tumor size (2.8 cm vs 4.0 cm, P = .001), lower incidence of positive surgical margins (8% vs 30%, P < .002), and less lymph node metastasis (45% vs 78%, P < .001).ConclusionsThe strategy of neoadjuvant therapy before surgical resection appears to offer pathologic effect and survival benefit for the patients presenting with non‐metastatic PDAC.
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.
Takeno, Atsushi , Makari, Youichi, Matsuyama, Jin , Sugimoto, Naotoshi , Taniguchi, Hirokazu , Nagai, Kenichi, Tamura, Shigeyuki , Nishijima, Junichi, Ueda, Shugo , Kimura, Yutaka , Tamura, Takao , Kobayashi, Kenji , Fujitani, Kazumasa , Sakai, Daisuke , Shimokawa, Toshio , Endo, Shunji , Kawabata, Ryohei , Kawakami, Hisato , Kurokawa, Yukinori , Satoh, Taroh

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 102-102

10.1200/jco.2018.36.4_suppl.102 Get It

102 Background: This phase II study aimed to investigate the safety and efficacy of XP compared to SP in the first-line treatment of HER2 negative AGC. Methods: Patients were randomly assigned to receive either SP (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/ m2 on day 8, every 5 weeks) or XP (capecitabine 1,000 mg/m2 twice daily for 14 days plus cisplatin 80 mg/m2 on day 1, every 3 weeks). Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), and adverse events. Results: 84 eligible patients were randomly assigned to receive SP ( N = 41) or XP ( N = 43). No statistical difference was observed in overall RR between the SP and XP groups [51.2% (95% CI, 35.1% to 67.1%) vs. 53.5% (95% CI, 37.7% to 68.8%), P = 1.000]. Despite not significant, however, SP vs. XP showed a trend toward better PFS [median, 5.9 months vs. 4.1 months; hazard ratio (HR), 0.763; 95% CI, 0.462 to 1.259; P = .284] and OS (median, 13.5 months vs. 10.0 months; HR, 0.776; 95% CI, 0.485 to 1.244; P = .290). This trend in the SP vs. XP comparison was more pronounced in TTF (median, 4.5 months vs. 3.1 months; HR, 0.651; 95% CI, 0.421 to 1.006; P = .052). Common grade 3 to 4 hematological toxicities were neutropenia and anemia (SP group, 23% and 23%; XP group, 35% and 28%). Grade 3-4 anorexia and hyponatremia were more frequently seen in the XP group (31% and 16%) compared to the SP group (13% and 5%). Treatment-related deaths occurred in one patient (2.3%) in the XP group. Conclusions: XP failed to demonstrate the superior efficacy over SP. Higher incidence of severe toxicities by XP suggests SP as the standard 1st line chemotherapy for HER2 negative AGC in Japan. Clinical trial information: UMIN000006755.